Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

BACKGROUND: Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 years in patients with rheumatoid arthritis (RA). METHODS: Eligible patients had previously completed a phase 1, 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Wollenhaupt, Jürgen, Lee, Eun-Bong, Curtis, Jeffrey R., Silverfield, Joel, Terry, Ketti, Soma, Koshika, Mojcik, Chris, DeMasi, Ryan, Strengholt, Sander, Kwok, Kenneth, Lazariciu, Irina, Wang, Lisy, Cohen, Stanley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451219/
https://www.ncbi.nlm.nih.gov/pubmed/30953540
http://dx.doi.org/10.1186/s13075-019-1866-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451219/
https://www.ncbi.nlm.nih.gov/pubmed/30953540
http://dx.doi.org/10.1186/s13075-019-1866-2

Ejemplares similares